First Time Loading...

Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 8.79 USD 5.4% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

RXRX Price Targets Summary
Recursion Pharmaceuticals Inc

Wall Street analysts forecast RXRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RXRX is 13.26 USD with a low forecast of 10.1 USD and a high forecast of 17.85 USD.

RXRX Lowest Forecast
Wall Street Target
10.1 USD
15% Upside
RXRX Average Forecast
Wall Street Target
13.26 USD
51% Upside
RXRX Highest Forecast
Wall Street Target
17.85 USD
103% Upside
Lowest
Price Target
10.1 USD
15% Upside
Average
Price Target
13.26 USD
51% Upside
Highest
Price Target
17.85 USD
103% Upside
Recursion Pharmaceuticals Inc Competitors:
Price Targets
FHTX
Foghorn Therapeutics Inc.
130% Upside
DCPH
Deciphera Pharmaceuticals Inc
6% Upside
1801
Innovent Biologics Inc
37% Upside
2256
Abbisko Cayman Ltd
162% Upside
FHTX
Foghorn Therapeutics Inc.
130% Upside
DCPH
Deciphera Pharmaceuticals Inc
6% Upside
1801
Innovent Biologics Inc
37% Upside
2256
Abbisko Cayman Ltd
162% Upside
R
RLYB
Rallybio Corp
589% Upside
C
688276
Changchun BCHT Biotechnology Co
62% Upside
DNLI
Denali Therapeutics Inc
150% Upside
NKTX
Nkarta Inc
161% Upside

Revenue
Forecast

Revenue Estimate
Recursion Pharmaceuticals Inc

For the last 3 years the compound annual growth rate for Recursion Pharmaceuticals Inc's revenue is 124%. The projected CAGR for the next 3 years is 51%.

124%
Past Growth
51%
Estimated Growth
Estimates Accuracy
-19%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Recursion Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Recursion Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
RXRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RXRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RXRX stock valuation using valuation multiples.
Wall Street Estimates
RXRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RXRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RXRX's stock price target?
Price Target
13.26 USD

According to Wall Street analysts, the average 1-year price target for RXRX is 13.26 USD with a low forecast of 10.1 USD and a high forecast of 17.85 USD.

What is Recursion Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
51%

For the last 3 years the compound annual growth rate for Recursion Pharmaceuticals Inc's revenue is 124%. The projected CAGR for the next 3 years is 51%.

ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.